BridgeMD
Compares treatment options for Skin Cancer Face
Official title Comparing Numbing Techniques in Mohs Micrographic Surgery
ClinicalTrials.gov ID: NCT07222241
What this study is testing
- What it's testing
- This study seeks to determine whether adjunct regional nerve blocks reduce pain and anxiety in adult patients undergoing Mohs micrographic surgery for face and scalp skin cancers. Participants will be randomized to one of two arms: (1) placebo regional nerve block with sterile normal saline or (2) adjunct regional nerve block with lidocaine.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 years.
- Scheduled to undergo MMS.
- Lesions on the face or scalp, defined as the region superior to the mandibular margin anteriorly, superior to the external occipital protuberance...
- Tumor diameter plus anticipated stage 1 MMS margin ≥2 cm in diameter OR any tumor on the ear, lip, nose, or eyelid.
- Ability to complete patient reported outcome measures in English.
You likely can't join if
- Known allergy or contraindication to lidocaine or epinephrine.
- Chronic opioid use or pre existing pain disorders that may interfere with pain reporting.
- Presence of scar tissue at the anatomic site of local infiltration or nerve block that may alter anesthetic penetration.
- Concurrent multi site Mohs procedure.
- Signs of skin and soft tissue infection at the anatomic site of local infiltration or nerve block.
- Inability to understand or complete pain and satisfaction assessments.
See the full eligibility criteria
- Age ≥18 years.
- Scheduled to undergo MMS.
- Lesions on the face or scalp, defined as the region superior to the mandibular margin anteriorly, superior to the external occipital protuberance posteriorly, and superior to the mastoid processes laterally.
- Tumor diameter plus anticipated stage 1 MMS margin ≥2 cm in diameter OR any tumor on the ear, lip, nose, or eyelid.
- Ability to complete patient reported outcome measures in English.
- Known allergy or contraindication to lidocaine or epinephrine.
- Chronic opioid use or pre existing pain disorders that may interfere with pain reporting.
- Presence of scar tissue at the anatomic site of local infiltration or nerve block that may alter anesthetic penetration.
- Concurrent multi site Mohs procedure.
- Signs of skin and soft tissue infection at the anatomic site of local infiltration or nerve block.
- Inability to understand or complete pain and satisfaction assessments.
- Pregnant or breastfeeding.
- Use of sedatives or anxiolytics prior to the procedure.
The study team makes the final eligibility decision.
Where it's taking place
- Philadelphia, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.